Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole

  • Hatsushi Yamagishi
  • , Tomoyuki Koike
  • , Shuichi Ohara
  • , Toru Horii
  • , Ryousuke Kikuchi
  • , Shigeyuki Kobayashi
  • , Yasuhiko Abe
  • , Katsunori Iijima
  • , Akira Imatani
  • , Kaori Suzuki
  • , Takanori Hishinuma
  • , Junichi Goto
  • , Tooru Shimosegawa

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Aim: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2, receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg. Methods: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug. Results: The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg. Conclusion: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ.

Original languageEnglish
Pages (from-to)2406-2410
Number of pages5
JournalWorld Journal of Gastroenterology
Volume14
Issue number15
DOIs
Publication statusPublished - 2008 Apr 21

Keywords

  • Antisecretory activity
  • H receptor antagonists
  • Lafutidine
  • Lansoprazole
  • Proton pump inhibitors

Fingerprint

Dive into the research topics of 'Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole'. Together they form a unique fingerprint.

Cite this